Moreau, P., Chari, A., Oriol, A., Martinez-Lopez, J., Haenel, M., Touzeau, C., . . . Goldschmidt, H. (2023). Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: Final analysis of PLEIADES and EQUULEUS. Blood cancer journal, 13, . https://doi.org/10.1038/s41408-023-00805-x
Chicago-Zitierstil (17. Ausg.)Moreau, Philippe, et al. "Daratumumab, Carfilzomib, and Dexamethasone in Relapsed or Refractory Myeloma: Final Analysis of PLEIADES and EQUULEUS." Blood Cancer Journal 13 (2023). https://doi.org/10.1038/s41408-023-00805-x.
MLA-Zitierstil (9. Ausg.)Moreau, Philippe, et al. "Daratumumab, Carfilzomib, and Dexamethasone in Relapsed or Refractory Myeloma: Final Analysis of PLEIADES and EQUULEUS." Blood Cancer Journal, vol. 13, 2023, https://doi.org/10.1038/s41408-023-00805-x.